We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+4.91%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$12B
AUM Growth
+$251M
Cap. Flow
-$39.8M
Cap. Flow %
-0.33%
Top 10 Hldgs %
36.53%
Holding
164
New
29
Increased
43
Reduced
30
Closed
27

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$255M
2
BSX icon
Boston Scientific
BSX
+$146M
3
ABBV icon
AbbVie
ABBV
+$121M
4
AGN.PRA
Allergan plc
AGN.PRA
+$109M
5
PBYI icon
Puma Biotechnology
PBYI
+$103M

Top Sells

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$207M
2
ZBH icon
Zimmer Biomet
ZBH
+$116M
3
MDVN
MEDIVATION, INC.
MDVN
+$115M
4
ACT.PRA
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
+$105M
5
SYK icon
Stryker
SYK
+$87.8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Financials 0.24%
3 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LAB icon
51
Standard BioTools
LAB
$325M
$59.3M 0.5%
2,449,900
+313,700
+15% +$9.9M
EXAS
52
DELISTED
Exact Sciences
EXAS
$52.9M 0.44%
1,778,000
– –
OTIC
53
DELISTED
Otonomy, Inc.
OTIC
$51.9M 0.43%
2,256,398
– –
INFI
54
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$48.4M 0.4%
4,416,300
+151,400
+4% +$1.94M
MDT icon
55
Medtronic
MDT
$113B
$47.9M 0.4%
+646,300
New +$49.4M
CMRX
56
DELISTED
Chimerix, Inc.
CMRX
$47.2M 0.39%
+1,021,600
New +$40.9M
CERS icon
57
Cerus
CERS
$577M
$43.1M 0.36%
8,307,727
– –
INSM icon
58
Insmed
INSM
$22.5B
$41.7M 0.35%
+1,708,500
New +$38.8M
SPY icon
59
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$775B
$41.2M 0.34%
+200,000
New +$42.1M
GWPH
60
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$39.9M 0.33%
325,000
+123,000
+61% +$14M
LOXO
61
DELISTED
Loxo Oncology, Inc
LOXO
$39.2M 0.33%
2,175,857
– –
PTLA
62
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$38.7M 0.32%
850,700
– –
BHC icon
63
Bausch Health
BHC
$1.7B
$36.7M 0.31%
165,000
+3,000
+2% +$665K
FWP
64
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$36.6M 0.31%
137,229
– –
XNPT
65
DELISTED
XENOPORT, INC.
XNPT
$35.4M 0.3%
5,768,400
+222,300
+4% +$1.45M
BMY icon
66
CALL
Bristol-Myers Squibb
BMY
$130B
$33.3M 0.28%
500,000
-500,000
-50% -$33M
HZNP
67
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$33M 0.28%
951,000
-124,000
-12% -$3.78M
KDNY
68
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$32.3M 0.27%
+213,104
New +$35.2M
PRQR icon
69
ProQR Therapeutics
PRQR
$243M
$30.5M 0.26%
1,831,400
– –
DYAX
70
DELISTED
DYAX CORPORATION
DYAX
$29.6M 0.25%
+1,117,000
New +$29.6M
UNH icon
71
UnitedHealth
UNH
$387B
$29M 0.24%
238,000
+3,000
+1% +$355K
ASMB icon
72
Assembly Biosciences
ASMB
$497M
$26.9M 0.22%
116,425
+3,925
+3% +$757K
LKFT
73
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$26.4M 0.22%
+512,900
New +$27.2M
SGYP
74
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$25.9M 0.22%
3,121,148
– –
BMRN icon
75
BioMarin Pharmaceuticals
BMRN
$12B
$25.7M 0.21%
+188,000
New +$23.3M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2015 Portfolio in Review

As of Q2 2015, OrbiMed held 164 positions worth $12B, up 2.1% from $11.7B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed's Q2 2015 filing shows 29 new, 43 increased, 30 reduced and 27 closed positions. Its largest new stake was Allergan plc: 104,200 shares worth $109M. The largest sale was Perrigo, an estimated $207M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2015 buy was Allergan plc: 104,200 shares worth $109M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2015, an estimated $255M increase.
  • OrbiMed's biggest Q2 2015 reduction was Zimmer Biomet, cutting an estimated $116M.
  • OrbiMed fully exited Perrigo in Q2 2015, selling an estimated $207M.
  • OrbiMed's ten largest holdings make up 37% of its $12B portfolio in Q2 2015.
  • OrbiMed opened 29 new positions and closed 27 in Q2 2015.
  • OrbiMed's portfolio value rose 2.1% quarter-over-quarter to $12B.

Based on OrbiMed's 13F filing for Q2 2015, filed 14 Aug 2015.